ID
45976
Beskrivning
Principal Investigator: Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Acute Kidney Injury https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000894 The goal of this study was to identify genetic variants associated with risk for acute kidney injury (AKI) in patients being treated with vancomycin and genetic variants associated with variability in vancomycin pharmacokinetics. AKI is a common adverse drug event and known complication of vancomycin therapy. Known risk factors fail to accurately predict renal toxicity. Our hypothesis, that genetic variants modify the risk of AKI, was tested by performing genome-wide association and linear regression in 429 patients of European descent using the outcome of peak serum creatinine while on vancomycin. We also tested the hypothesis that genetic variants associate with vancomycin pharmacokinetics, using vancomycin trough levels and calculated renal elimination rate constant as outcomes.
Länk
Nyckelord
Versioner (1)
- 2024-04-02 2024-04-02 - Madita Rudolph
Rättsinnehavare
Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA
Uppladdad den
2 april 2024
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs000894 Genome Wide Study of Vancomycin
Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- Subject - Sample Mapping
- The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
Similar models
Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- Subject - Sample Mapping
- The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
C0441833 (UMLS CUI [1,2])